FDA Approved: EMFLAZA — Supplemental Application (PTC Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Emflaza (deflazacort) by PTC Therapeutics, expanding the drug’s labeling. The update concerns Duchenne muscular dyst…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• EMFLAZA (deflazacort)

Snippet

SUPPL AP for EMFLAZA (DEFLAZACORT)